2006 Press Releases Communiqués de presse

December 19, 2006 19 December, 2006

Results of Toronto Hospital Study of Diabetic Mice Supports Sernova Corp's Cellular Therapy Technology

December 4, 2006 4 December, 2006

Leading Virologist Dr. Clive Patience Appointed to Help Guide the Development of Sernova's Proposed Diabetes Product

December 1, 2006 1 December, 2006

Breakthrough Magnetic Resonance Imaging Technique Developed for Diabetes's Cellular Therapy: Published in November Issue of Medical Journal, "Diabetes

October 23, 2006 23 October, 2006

Sernova's Research Following Latest NIH Guidelines for Type 1 Diabetes

October 2, 2006 2 October, 2006

Sernova's Sertoli Cell Research Hopes to Replace Anti-Rejection Drugs in Edmonton Protocol Islet Transplants for Diabetics

September 25, 2006 25 September, 2006

Dr. George Adams Appointed to Board of Directors to Help Commercialize Insulin Dependent Diabetes Product

September 20, 2006 20 September, 2006

Diabetic Product Development Leads to Name Change: Sernova Corp.

August 1, 2006 1 August, 2006

Pheromone Builds Scientific Advisory Board: Sertoli Cell Expert Dr. Jannette Dufour to Help Develop Diabetes Product

July 28, 2006 28 July, 2006

Business Advisory Board Established to Commercialize Diabetes Product

July 25, 2006 25 July, 2006

Pheromone's Principal Researcher to Present 'Diabetes Reversal Model' at World Transplant Congress

July 19, 2006 19 July, 2006

Pheromone Builds Scientific Advisory Board: Appoints Dr. Norman Wong to Help Develop Diabetes Product

July 10, 2006 10 July, 2006

Charles Allard Appointed to Board of Directors

June 26, 2006 26 June, 2006

Justin Leushner Appointed to Board of Directors

June 19, 2006 19 June, 2006

Dr. David White to Become Principal Researcher and Chair of Scientific Advisory Board

May 25, 2006 25 May, 2006

Pheromone Receives TSX Approval of Joint Venture and Completes $3.2 Million Financing

April 3, 2006 3 April, 2006

Pheromone Sciences Increases Private Placement

March 20, 2006 20 March, 2006

Pheromone Sciences Signs Joint Venture Agreement for New Research Project

March 20, 2006 20 March, 2006

Pheromone Issues Stock Options

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 19, 2006 19 December, 2006

Results of Toronto Hospital Study of Diabetic Mice Supports Sernova Corp's Cellular Therapy Technology


Kelowna, B.C. -- Sernova Corp. today announced it is encouraged by the results of the study conducted with diabetic mice by Toronto researchers, and subsequently reported by several Canadian news outlets. The results appear to support Sernova's approach to treating diabetes in that Sertoli cells secrete, among other things, "substance P," the neuropeptide Toronto researchers injected into diabetic mice to reverse new onset diabetes. Sernova's approach to treating diabetes is to implant beneath the skin of diabetics, a small device containing insulin producing islets to reverse diabetes, and Sertoli cells to naturally protect the islets from the body's immune system.

Sernova's chief scientist, Dr. David White was intrigued by the press reports, although he noted that these are preliminary studies and the approach does not address subjects that already have diabetes. He states, "It has been known for several years that Sertoli cells secrete tachykinins such as substance P. The recent news from Toronto would seem to confirm our belief that these secretions are an important component in generating the protective effect of Sertoli cells for islets. Substance P is a pain transmitter and induces vomiting. Therefore we maintain that the best approach is to replace the insulin producing cells that have been destroyed along with protective Sertoli cells, that we know secrete Substance P along with other important growth factors and immunoprotective compounds. We have also known for some time that Sertoli cells can prevent diabetes in the same strain of mice that the Toronto group used."

Sernova President Justin Leushner said, "The recent press coverage of this study confirms that a cure for diabetes is at the forefront of people's attention and that is why we are moving forward toward commercializing Sertolin our diabetes therapy, which is targeted for human diabetics."

Sernova's research is focused on compiling pre- clinical data to support an Investigational New Drug application to the United States Food and Drug Administration for their Sertolin Diabetes Therapy. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Sernova Corp.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 04, 2006 4 December, 2006

Leading Virologist Dr. Clive Patience Appointed to Help Guide the Development of Sernova's Proposed Diabetes Product


Kelowna, B.C. -- Sernova Corp. ("Sernova") is pleased to announce that Dr. Clive Patience Ph.D. has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.

"Dr. Patience is one of the world's leading experts on biological safety of xenotransplantation, and is a supporter of Sernova's emerging diabetes technology." stated Dr. David White, Chair of Sernova's SAB. "Our research team will be enhanced by his intimate understanding of biological safety, while his knowledge of the FDA process will assist us in moving this technology to the clinic."

Dr. Patience is currently the Associate Director of Bioanalytical Quality Control at Biogen Idec. Inc. (NASDAQ: BIIB) in Cambridge Massachusetts. For several years previously he directed research on porcine retroviruses and herpesviruses, and in a 3 year study demonstrated the acceptable microbiological safety of pig to non-human primate transplants. He has also been an invited speaker to FDA safety committees..

About Dr. Patience Dr. Patience obtained his Ph.D in virology from the University of London while working as a research scientist at the Institute of Cancer Research in London England, Much of his research focused on the biology of HIV, porcine endogenous retroviruses, and retroviral/adenoviral gene therapy vectors. He later accepted a position in Massachusetts as Director of Microbiological Safety with Immerge Bio Therapeutics, a world leader in research to genetically modify pigs for organ transplants. In 2004 he joined Biogen Idec as a Senior Scientist before ascending to his current position. His research has been published in many peer reviewed journals including Nature Medicine, the Journal of Virology and the American Journal of Transplantation. Dr. Patience has also contributed chapters to several medical books.

About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner" Justin Leushner, President

For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Executive Vice President Sernova Corp.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 01, 2006 1 December, 2006

Breakthrough Magnetic Resonance Imaging Technique Developed for Diabetes's Cellular Therapy: Published in November Issue of Medical Journal, "Diabetes"


Kelowna, B.C. -- Sernova Corp. ("Sernova") is pleased to announce the November issue of the medical journal, Diabetes, has published a breakthrough MRI method for monitoring the viability of transplanted pancreas islets. The technique was developed by the research group led by Dr. David White, Chair of Sernova's Scientific Advisory Board, in collaboration with Dr. Paula Foster and the imaging group at the Robarts Research Institute in London, Ontario.

The breakthrough imaging method will empower physicians and researchers to monitor the survival of transplanted, insulin-producing islet clusters in patients treated with the "Edmonton Protocol." Sernova will use the technique to verify the longevity of islets in its cellular therapy approach of transplanting both Sertoli and islet cells.

"This is an important development for Sernova because real time tracking of islets gives immediate feedback to our research team on the success of transplant experiments," said Sernova President Justin Leushner. "It will also provide valuable data for the FDA and other health regulators on the long-term efficacy of cellular therapy for diabetes."

About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Executive Vice President Sernova Corp.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 23, 2006 23 October, 2006

Sernova's Research Following Latest NIH Guidelines for Type 1 Diabetes


News Releases October 23, 2006 Sernova's Research Following Latest NIH Guidelines for Type 1 Diabetes Kelowna, B.C. - Sernova Corp.'s ("Sernova") cell replacement research for the company's diabetes product development project is in line with the recently released recommendations of the US National Institute of Health's ("NIH") long range plan for diabetes research.

Entitled "Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan," one of NIH's stated goals is the development of new and improved cell replacement therapies - exactly the focus of Sernova's diabetes research.

The NIH plan recognizes the advances pioneered by the Edmonton Protocol, but the plan identified four barriers preventing cell replacement from becoming a viable treatment for a large number of diabetics. Current research by Sernova Corp demonstrates its technology may overcome those key barriers described below: ------------------------------+------------------------------ ----- NIH Noted Barrier | Sernova Solution ------------------------------+------------------------------ ----- Develop methods to produce | Use virtually unlimited supply an unlimited supply of | of pig cells, (Pig insulin islets | is compatible with humans) ------------------------------+------------------------------ ----- Improve ways to harvest | Size of pig cell supply allows islets | harvesting to be less than | optimally efficient without any | noticeable economic impact or | timing delays ------------------------------+------------------------------ ----- Reduce complication of islet | Small device for containing cells transplantation | is implanted just below the skin | in a 10 minute operation under | local anaesthetic. ------------------------------+------------------------------ ----- Prevent recurrent | When Sernova's patented Sertoli autoimmunity and the immune | cells are transplanted with the rejection of donor islets | islets in the device, a naturally | protected, immunoprivileged site | is created which minimizes or | eliminates the body's immune | response to the foreign cells. ------------------------------+------------------------------ ----- Stated Sernova President Justin Leushner, "The NIH's plan underscores the importance of developing an effective and commercially viable cell replacement therapy for insulin dependent diabetes. We believe our research and technology will lead to the breakthrough NIH envisions."

Sernova's research is currently compiling pre- clinical data to support an Investigational New Drug application to the United States Food and Drug Administration. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Executive Vice President Sernova Corp.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 02, 2006 2 October, 2006

Sernova's Sertoli Cell Research Hopes to Replace Anti-Rejection Drugs in Edmonton Protocol Islet Transplants for Diabetics


Kelowna, B.C. -- Sernova Corp. ("Sernova") notes with interest the positive results of a recent international trial of islet transplantation for the reversal of diabetes. Published last week in the New England Journal of Medicine and subsequently reported by many media outlets, this study of the "Edmonton Protocol" also revealed the failure of anti-rejection drugs to adequately protect the transplanted, insulin producing islets.

While the trial clearly demonstrated the benefits of islet transplantation, with more than half of the patients becoming insulin independent after one year, by two years posttransplant 76% of these patients were again requiring some insulin treatment. The subjects continued to benefit from the treatment after two years, but the authors concluded too many of the islets were killed by the immune system for most subjects to remain insulin free.

Stated Sernova President Justin Leushner, "This study confirms that overcoming the body's immune response to the islet transplants is still the biggest hurdle to making the treatment successful. We believe the use of our proprietary Sertoli cell technology may finally solve this problem."

To overcome the immune system response, Sernova's proposed solution is to use the Sertoli cell's proven ability to create a immunologically protected environment for transplanted cells. The working hypothesis presupposes that once islets and Sertoli cells are injected into a small vascularized chamber implanted below the skin, the islets can produce insulin in response to the body's demands while the Sertoli cells protect the islets by masking their presence from the immune system. This ongoing research is built upon several proof-of-concepts experiments already completed by Dr. David White, Sernova's principal researcher, and others.

Sernova's research is focused on compiling pre- clinical data to support an Investigational New Drug application to the United States Food and Drug Administration. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

About Sernova Sernova Corp. is a Canadian based, biotechnology research and development company focused on commercializing medical technologies. Current emphasis is to successfully commercialize a potential breakthrough product for insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO For further information contact: TEL: (888) 318-7062 Phil Morehouse FAX: (250) 868-8493 Sernova Sciences Corp. info@sernovacorp.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 25, 2006 25 September, 2006

Dr. George Adams Appointed to Board of Directors to Help Commercialize Insulin Dependent Diabetes Product


Kelowna, B.C. -- Sernova Corp. ("Sernova") is pleased to announce that Dr. George Adams of Toronto, Ontario has been appointed to the Board of Directors to assist Sernova in moving its diabetes product development to the commercialization stage.

"Dr. Adams' success as both a scientist and an entrepreneur makes him an ideal fit for our board." said Sernova's Chairman Dr. William Cochrane. "His extensive experience in financing start-ups and effectively commercializing medical research will be very helpful."

Dr. Adams has been a founding angel investor in six start- up companies in Canada and the United States and was instrumental in obtaining venture financing for 24 companies who have raised a total of $85 million. He has also been a Director of 10 venture capital funds and 8 start-up companies.

Dr. Adams has published his work in 124 publications including 9 invited reviews, 26 full papers and 3 patents. He is a past President of the Canadian Biomaterials Society. He has been a reviewer for numerous scientific journals, national granting agencies and several national and provincial centres of excellence. He has been a principal investigator for over $40 million in private and publicly-funded research and development.

About Dr. George Adams Dr Adams obtained his Ph.D. in Medical Sciences from McMaster University after completing his B.A.Sc. and M.A.Sc. in Mechanical Engineering at the University of Waterloo. After a postdoctoral year at the Baylor College of Medicine studying vascular biology, he became a Senior Scientist in the Canadian Red Cross Blood Transfusion Service. He then accepted a position with the University of Ottawa as the Director of its Artificial Heart Development Program and an Associate Professor of Biochemistry and Surgery.

Dr. Adams left his position at the University of Ottawa to start his own company and developed a diagnostic product, which were subsequently commercialized by DuPont Canada Inc. In 1994 he became the controlling shareholder and President of Corvita Canada and financed its research program until the company was purchased by Pfizer in 1996 and later re-sold to Boston Scientific in 1998. From 1999 through 2004, Dr. Adams was Chief Executive Officer of the University of Toronto Innovations Foundation. Since 2005, he has served as the Chief Executive Officer and a Director of Amorfix Life Sciences Ltd.

About Sernova Sernova Corp. is a Canadian based, biotechnology research and development company focused on commercializing medical technologies. Current emphasis is to successfully commercialize a potential breakthrough product for insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD "Dev Randhawa" Dev Randhawa, CEO

For further information contact: Mr. Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 20, 2006 20 September, 2006

Diabetic Product Development Leads to Name Change: Sernova Corp.


Kelowna, B.C. - Pheromone Sciences Corp. is pleased to announce it has changed its name to Sernova Corp. ("Sernova"). The company's new stock symbol is SVA.

"The new name fits better with projects such as our current development of a potential breakthrough treatment for diabetes," said Chairman Dr. William Cochrane. "We wanted a new name to help make it clear to investors that our focus is no longer centred around pheromones, but can include all kinds of biotechnology developments."

Shareholders approved the name change at the Company's annual general meeting held on August 18th 2006 and elected 5 directors to the Board: Dr. William Cochrane (Chair), Charles Allard, Justin Leushner, Devinder Randhawa and Dr. Eldon Smith.

The Company's officers are: Chief Executive Officer- Devinder Randhawa, President-Justin Leushner, and Chief Financial Officer and Corporate Secretary-Patrick Groening.

Sernova Corp. is a biotechnology research and development company focused on commercializing medical technologies.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact: TEL: (888) 318-7062 Mr. Phil Morehouse FAX: (250) 868-8493 Sernova Corp.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 01, 2006 1 August, 2006

Pheromone Builds Scientific Advisory Board: Sertoli Cell Expert Dr. Jannette Dufour to Help Develop Diabetes Product


Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. Jannette Dufour, PhD has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.

"Because Sertoli cells are a key component of our project, Dr. Dufour's extensive research into these cells significantly enhances our team," stated Dr. David White, Chair of Pheromone's SAB. "Her experience working for the University of Alberta's Clinical Islet Transplant Program [originators of the prominent 'Edmonton Protocol'] will be particularly valuable."

Currently Assistant Professor in the Department of Cell Biology and Biochemistry at Texas Tech University Health Sciences Center in Lubbock Texas, Dr. Dufour's research was instrumental in developing the technology leading to some of the Sertoli cell patents now licensed exclusively to Pheromone. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

About Dr. Dufour In 1999 Dr. Dufour received a PhD in Genetics and Cell Biology from Washington State University, where she first began research on Sertoli cells as a graduate student. She then went on to receive further training as a postdoctoral fellow with Drs. Rajotte and Korbutt with the Islet Transplantation Program at the University of Alberta. While there she received five postdoctoral fellowships to study the use of Sertoli cells as a way to immunoprotect transplanted islets. Dr. Dufour is now an Assistant Professor at Texas Tech University Health Sciences Center where she continues to investigate the immunoprotective properties of Sertoli cells with the goal of developing ways to improve the survival of transplanted islets.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact: Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 28, 2006 28 July, 2006

Business Advisory Board Established to Commercialize Diabetes Product


Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce that it has established a Business Advisory Board to strategically guide the directors and management in commercializing the Company's diabetes product. Pheromone has appointed three former Company directors to the board: William Milligan, Andrew Saxton and Christopher Neuman.

"These men all have an intimate understanding of the Company and the business of biotechnology," said Dr. William Cochrane, Chairman of the Board of Directors. "We are glad Pheromone will continue to get the benefit of their expertise and wisdom."

About William Milligan Since 2002 Mr. Milligan has served as the Chief Business Officer of Migenix Inc. (TSX: MGI), a biopharmaceutical company focused on innovative drugs for life- threatening diseases. He has extensive experience in leading and managing pharmaceutical commercialization, financing, product development, licensing and strategic alliances from both large pharmaceutical and small biotechnology companies. Mr. Milligan was previously President & CEO of Cytran Inc., a private biotechnology company based in Seattle, and CEO of Intellivax International Inc., a private biotechnology company based in Montreal and Baltimore. Prior to that he worked for Hoffmann-La Roche Ltd. (Canada) and Eli Lilly Inc. (Canada). At Roche, he held Vice President positions in Pharmaceuticals including: Business Development and New Product Planning, Sales Division, and Biomedical Division. Mr. Milligan served as a Director of Pheromone from 2000-2006.

About Andrew Saxton Mr. Saxton is currently Chairman of the King George Financial Corporation and has had a long and successful career of leadership roles in finance, commercial real estate and insurance. He is currently a Director of Canadian Commercial Corporation (a Federal Crown Corporation), Earthworks Industries Inc., Imperial Parking Canada Corporation, and the University of British Columbia Investment Management Trust. He was previously the co-founder and Executive Vice President of Laurentide Financial Corporation, founder and President of Elite Insurance and Chairman of Grouse Mountain Resorts Ltd. He has been a Director with of several companies including BCTV, the Commonwealth Bank of Nassau Bahamas, and the Insurance Corporation of British Columbia, where he chaired the Investment Committee. He has served on many advisory boards including the World Heart Federation, the BC Life Sciences Fund and the Dean of Faculty of Medicine's Community Advisory board at the University of British Columbia. From 2000- 2006 Mr. Saxton was a director of Pheromone.

About Christopher Neuman Mr. Neuman was a director of Pheromone from 2000 to 2006, serving as its CEO until 2005. He has 35 years experience in the Canadian health care industry, including positions as General Manager of ALZA Canada, and President and General Manager of Baker Cummins Inc. He held senior management positions with Marion Merrell Dow Inc., PharmaScience Inc., Boots Pharmaceuticals Ltd. and Neuromedical Systems Inc., where, as General Manager, he was responsible for the establishment of a Canadian subsidiary for the U.S. diagnostics company. His early career included production & operations management, positions at Davis+Geck/Lederle Laboratories, Elliot-Marion Co. Ltd., and sales and sales & marketing management positions at Beecham Laboratories Inc.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.



ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact: Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 25, 2006 25 July, 2006

Pheromone's Principal Researcher to Present 'Diabetes Reversal Model' at World Transplant Congress


PHS 2006-09

Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. David White, principal researcher on the Company's 'Diabetes Reversal' product development, will present his latest research results at the World Transplant Congress in Boston on Friday, July 28th.

In a special session convened by the International Xenotransplant Association, Dr White will unveil the experimental model (pig to rat) in which he demonstrated enhanced suppression of the host's immune system to allow for long term survival of implanted, insulin- producing islet cells.

Dr. White's model is the basis for Pheromone's research project on reversing diabetes by co-transplanting two types of pig cells in an implanted device: (a) islet cells which produce insulin compatible for humans, and (b) Sertoli cells which will naturally protect those injected islet cells from attack by the body's immune defence system. Pheromone owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

By using rigorous and widely accepted scientific experimentation methods, Pheromone's goal is to receive approval for this cellular therapy product from the United States Food and Drug Administration, and from other national regulatory bodies throughout the world.

About Dr. White

Dr White graduated from the Universities of Surrey and Cambridge and in 1975 was awarded a PhD in Immunology from Cambridge. He was Board Certified in Pathology in 1984 (MRCPath) and elected as a fellow of the college in 1995 (FRCPath). Dr White holds appointments on the Editorial Board of several major international transplantation journals, has served as a member of government advisory committees, and has been awarded a number of academic prizes for his work. He has published over 300 scientific papers on subjects related to transplant immunology.

Dr. White first became interested in transplantation while undertaking research at the Department of Surgery at Cambridge University in the 1970s. In conjunction with Professor Sir Roy Calne, he undertook much of the original experimental and clinical work that led to the development of the immunosuppressive drug Cyclosporin A. The drug became pivotal in preventing organ rejection following transplantation and has allowed new transplantation procedures to be developed.

His research into the immunological process underlying rejection of organ transplants led him to investigate how the immune system could be modified to enable successful transplantation of non-human organs - potentially solving the 'organ donor crisis'. These studies led Dr White in 1992 to create the world's first genetically engineered pigs whose organs and tissues were modified for transplantation into humans. In 1984 he and transplant surgeon John Wallwork founded Imutran Limited, which became a wholly owned subsidiary of Novartis Pharma AG in 1996., and Dr White was appointed to the Novartis Global Research Management Board. In 2000 Dr White was appointed the Novartis/Stiller Professor of Xenotransplantation at the University of Western Ontario.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact:

TEL: (250) 868-8177 FAX: (250) 868-8493

Mr. Phil Morehouse Pheromone Sciences Corp.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 19, 2006 19 July, 2006

Pheromone Builds Scientific Advisory Board: Appoints Dr. Norman Wong to Help Develop Diabetes Product


Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. Norman Wong, M.D., F.R.C.P.(C), has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.

"With extensive experience in researching and treating diabetes mellitus, Dr. Wong is an important addition to our Scientific Advisory Board," stated Dr. David White, Chair of Pheromone's SAB. "His medical career has demonstrated both his commitment to the treatment of diabetes and his ability to commercialize research findings."

Dr. Wong is the co-founder of Resverlogix Corp. (TSX: RVX) and serves as the Chairman of its SAB. He is also the Director of the Libin Gene Therapy Unit and is a Professor in both the departments of Medicine and Biochemistry & Molecular Biology at the University of Calgary.

About Dr. Wong Dr. Wong graduated from the University of Calgary, Faculty of Medicine in 1980, completed his internal medicine residency in 1983, and then received his fellowship training in endocrinology at the University of Minnesota. His research interest deals primarily with the molecular actions of hormones and specifically that related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. He has published numerous articles in the field of diabetes research. His clinical interest encompasses patients with diabetes mellitus or thyroid disease. In addition to his current positions, he has previously held posts at the University of Calgary. as Associate Vice-President of Research and International, and Assistant Dean (Research) Faculty of Medicine.

About the Diabetes Research Project Pheromone has recently completed a $3.2 million private placement to fund its research into an innovative treatment for Type 1 (insulin dependent) diabetes. Currently approved transplant procedures for reversing diabetes are rarely used because of the lack of suitable human organ donors and the need for patients to use immune suppressing anti-rejection drugs for the rest of their lives. Pheromone is in the process of developing a procedure to overcome these limitations by inserting into an implantable device two types of pig cells: islet cells that produce insulin compatible with humans, and Sertoli cells which will naturally protect the islet cells from attack by the body's immune system.

Using rigorous and widely accepted scientific experimentation methods, Pheromone's goal is to receive approval for this cellular therapy product from the United States Food and Drug Administration, and from other national regulatory bodies throughout the world. The research is based on several proof-of-concept studies completed by Dr. David White, Pheromone's principal researcher, and others. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact:

Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 10, 2006 10 July, 2006

Charles Allard Appointed to Board of Directors


Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Mr. Charles Allard, LLB of Edmonton, Alberta, has been appointed to the Board of Directors to assist Pheromone in its diabetes product development. Mr. Allard brings with him a history of successful business ventures in many fields including broadcasting, banking and real estate development.

Mr. Allard is presently a Director of Canadian Western Bank, Cathton Holding Ltd. and Allarco Entertainment Inc., and is President of Rosedale Meadow Developments Inc. He previously held board positions with WIC Premium Television Ltd., Canadian Satellite Communications Corp., ExpressVu Inc., Western International Communications Inc. The Family Channel, Teletoon, Northwest Trust Company and Allarco Developments. He has also recently been appointed a Director of the Alberta Diabetes Institute Advisory Board. He is active in several charitable organizations and serves as a Director of Young Life of Canada.

Mr. Allard completed his law degree at the University of British Columbia after graduating from Simon Fraser University's Bachelor of Science program. He was admitted to the Alberta Bar in 1973 and has practiced law continuously since then.

"We are delighted to have Mr. Allard join with us in moving this company towards a breakthrough in diabetes treatment," said Pheromone's Chairman Dr. William Cochrane. "He has shown his commitment to improving the lives of people with diabetes through his investments and charitable support of diabetes treatment and research."

About the Research Project Pheromone has recently completed a $3.2 million private placement to fund its research into an innovative treatment for Type 1 (insulin dependent) diabetes. Using rigorous and widely accepted scientific experimentation methods, the Company intends to develop a procedure for transplanting into humans a device containing pig islet cells and pig Sertoli cells. The islet cells produce insulin almost identical to that found in humans and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The goal of the project is to ultimately receive approval for the procedure from the United States Food and Drug Administration, and from other national regulatory bodies throughout the developed world. The research is based on several proof- of-concept experiments completed by Dr. David White, Pheromone's principal researcher, and others.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.



ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact:

Mr. Phil Morehouse Pheromone Sciences Corp.

TEL: (250) 868-8177 FAX: (250) 868-8493

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 26, 2006 26 June, 2006

Justin Leushner Appointed to Board of Directors


Kelowna, B.C. -- To facilitate the progress of its diabetes product development project, Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Mr. Justin Leushner of London, Ontario, has been named President of the Company, effective immediately. In addition, Mr. Leushner has been appointed to the Board of Directors. He is currently the manager of the Islet Transplant Program at the London Health Sciences Centre's ("LHSC") world renowned Multi-Organ Transplant Program. His role as President will include primary responsibility for monitoring the progress of Pheromone's diabetes research project being conducted at the LHSC's facilities. The project is Pheromone's primary research focus and is being funded by the Company's recently completed $3.2 million financing.

"Mr. Leushner brings with him a thorough knowledge of the research goals and possibilities of the technology we will be developing," said Pheromone Chief Executive Officer Dev Randhawa. "His balance of business acumen and scientific understanding makes him an excellent representative of our company's profile."

Mr. Leushner is also President and 50 percent shareholder in Sertonex Inc., a private London Ontario based company Pheromone is acquiring in stages as a result of Pheromone exercising its option under a recent joint venture and financing agreement with Sertonex and Sertoli Technologies Inc. of Tucson, Arizona. Under the terms of that agreement, Sertonex and Sertoli Technologies both have the right to nominate one member to Pheromone's board.

About Justin Leushner Mr. Leushner has had an extensive and diverse business career in the life sciences and biotechnology industries. He has participated in many entrepreneurial start-up companies, which have included consumer products, new technologies and biotechnology. He was also responsible for developing a national molecular diagnostics program for MDS Inc., Canada's largest life science's company, and served as a business analyst and portfolio advisor to the Canadian Medical Discoveries Fund. In 2004, Mr. Leushner co-founded Sertonex Inc. with Dr. David White, now Pheromone's primary researcher on the diabetes project.

An MBA graduate of the University of Western Ontario's Ivey School of Business, Mr. Leushner also holds a B.Sc. in Cell Physiology/Genetics from the University of British Columbia and numerous technical designations in Forensic Science and Molecular Biology.

About the Research Project Pheromone's research project is intended to lead to a procedure approved by the U.S. Food and Drug Administration for treating diabetes by transplanting into humans a device containing pig islets and Sertoli cells. The islet cells produce insulin almost identical to that found in humans, and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The research is based on several proof-of-concept experiments completed by Dr. White and others.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.



ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, President

For further information contact:

TEL: (250) 868-8177 Mr. Phil Morehouse FAX: (250) 868-8493 Pheromone Sciences Corp.

TEL: (519) 639-7867 Mr. Justin Leushner FAX: (519) 858-5142 Sertonex Inc.

TEL: (520) 748-4458 Ms. Jan McCoy Hutchinson FAX: (520) 748-0025 Sertoli Technologies Inc.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 19, 2006 19 June, 2006

Dr. David White to Become Principal Researcher and Chair of Scientific Advisory Board


Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. David White of the University of Western Ontario has agreed to become the principal researcher for the Company's diabetes research project and has accepted an appointment as Chair of the Company's Scientific Advisory board ("SAB"). Pheromone recently completed a $3.2 million private placement to fund this project, and it will be the Company's primary research focus.

As SAB Chair, Dr. White's first responsibility is to recruit members to the SAB who have significant standing in the community of diabetic and xenotransplantation researchers. "The scientists on the SAB shortlist are some of the finest minds in the field and they have an intricate understanding of the science of this project, " states Dr. White. "I believe their contributions will be invaluable in ensuring the best design and execution of this diabetes product development project"." The SAB will provide oversight of the Company's research efforts and provide scientific input and interpretation of the project's methodology, progression and results.

About Dr. White

Dr White graduated from the Universities of Surrey and Cambridge and in 1975 was awarded a PhD in Immunology from Cambridge. He was Board Certified in Pathology in 1984 (MRCPath) and elected as a fellow of the college in 1995 (FRCPath). Dr White holds appointments on the Editorial Board of several major international transplantation journals, has served as a member of government advisory committees, and has been awarded a number of academic prizes for his work. He has published over 300 scientific papers on subjects related to transplant immunology.

Dr. White first became interested in transplantation while undertaking research at the Department of Surgery at Cambridge University in the 1970s. In conjunction with Professor Sir Roy Calne, he undertook much of the original experimental and clinical work that led to the development of the immunosuppressive drug Cyclosporin A. The drug became pivotal in preventing organ rejection following transplantation and has allowed new transplantation procedures to be developed.

His research into the immunological process underlying rejection of organ transplants led him to investigate how the immune system could be modified to enable successful transplantation of non-human organs - potentially solving the 'organ donor crisis'. These studies led Dr White in 1992 to create the world's first genetically engineered pigs

whose organs and tissues were modified for transplantation into humans. In 1984 he and transplant surgeon John Wallwork founded Imutran Limited, which became a wholly owned subsidiary of Novartis Pharma AG in 1996., and Dr White was appointed to the Novartis Global Research Management Board. In 2000 Dr White was appointed the Novartis/Stiller Professor of Xenotransplantation at the University of Western Ontario.

About the Research Project

Pheromone's research project is intended to lead to an USFDA licensed procedure for treating diabetes by transplanting into humans a device containing pig islet and Sertoli cells. The islet cells produce insulin almost identical to that found in humans, and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The research is based on several proof of concept experiments completed by Dr. White and others.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies.

ON BEHALF OF THE BOARD "Dev Randhawa" Dev Randhawa, President

For further information contact:

Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

Mr. Justin Leushner Sertonex Inc. TEL: (519) 639-7867 FAX: (519) 858-5142

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 25, 2006 25 May, 2006

Pheromone Receives TSX Approval of Joint Venture and Completes $3.2 Million Financing


KELOWNA, BRITISH COLUMBIA - PHEREMONE SCIENCES CORP. (the "Company") is pleased to announce that it has received TSX Venture approval to proceed with the Company's previously announced joint venture and financing agreement with Sertonex Inc. (Sertonex) of London Ontario and Sertoli Technologies Inc. (STI) of Tucson Arizona. The purpose of the joint venture is to develop a commercially viable treatment for Type 1 human diabetes using transplanted devices containing pig cells. The Company intends to exercise its option under the terms of the agreement and to begin the research project.

Under the terms of the October 31, 2005 agreement, Pheromone has the exclusive right to acquire 100% of the project by providing funding of up to $3,500,000 in three stages. The first financing of $1,000,000 is due within 90 days of Exchange approval, the second financing of $1,000,000 within 6 months and the third financing of $1,500,000 must occur within 12 months of Exchange approval. As each stage of the project is financed, Pheromone will acquire one third of the project by issuing 2,315,000 shares to the two shareholders of Sertonex, Dr. David White and Mr. Justin Leushner. Mr. Leushner will join the board of directors of the Company and Dr. White will be engaged as the principal researcher on the project.

As part of the agreement, STI will exclusively license to Pheromone all patents, and patent applications for the therapeutic use of Sertoli cell technology. In exchange, Pheromone will issue to STI 6,527,500 common shares upon completion of the first project financing of not less than $1 million and nine months after closing pay STI a licensing fee of $1,142,312. STI is controlled by Research Corporation Technologies, Inc., a not for profit organization setup to facilitate the commercialization of bio medical research. Mr. Charles R. Allard of Edmonton, Alberta will join the board of directors on behalf of STI.

About the Research Project

The research will be conducted by Dr. David White of Sertonex, a noted immunologist trained at the University of Cambridge in England, where he was instrumental in the development of cyclosporin A, and later became a Post Doctoral Research Fellow in the Department of Surgery. While at Cambridge Dr. White started a company called Imutran where he held the post of Director of Research and was on the Novartis Global Research Board. Imutran was sold to Novartis and Dr. White accepted a post at the Robarts Research Institute in London Ontario where he is the Professor of Xenotransplantation.

The research project is intended to lead to an USFDA licensed procedure for treating diabetes by transplanting into humans a device containing pig islet and Sertoli cells. The islet cells produce insulin almost identical to that found in humans, and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The research is based on several proof of concept experiments completed by Sertonex and others.

Financing Completed

Concurrently, the Company is pleased to announce it has completed its non-brokered private placement of 8,072,750 units at $0.40 per unit for gross proceeds of $3,229,100. Each unit consists of one common share and one-half of one common share purchase warrant. Each whole common share purchase warrant entitles the holder to acquire one common share of the Company at a price of $0.60 for a period of 24 months following the closing date of the financing. Pheromone reserves the right to force the exercise of the warrants if the stock trades at a 10 day moving average above $1.00 per share. Finders fees of 7% of the proceeds raised will be paid as follows: Blackmont Capital: $76,685, National Bank Financial: $11,900, Canaccord Capital Corp.: $22,400, Edwin Slater: $8,400. Proceeds of the placement will be used to complete the first $1,000,000 stage of the research project and general operating purposes.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies.

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, President

For further information contact: TEL: (250) 868-8177 Mr. Phil Morehouse FAX: (250) 868-8493 Pheromone Sciences Corp.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 03, 2006 3 April, 2006

Pheromone Sciences Increases Private Placement


Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") announces that further to its release on March 20, 2006, Pheromone has increased the private placement to a maximum of $3,000,000.

The private placement is subject to regulatory and TSX Venture Exchange approvals. Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, President

For further information contact: Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 20, 2006 20 March, 2006

Pheromone Sciences Signs Joint Venture Agreement for New Research Project


Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce it has completed its due diligence review of the Sertoli Technologies Inc. ("Sertoli") patents and has entered into a joint venture agreement to finance the development of the project with Sertonex, Inc. of London Ontario, as previously announced on October 11, 2005. Pheromone has the exclusive right to acquire, in stages, 100% of the project by providing funding of up to $3,500,000 in three stages. As each stage of the project is financed, Pheromone has the right to acquire one third of the project by issuing 2,315,000 shares.

As part of the agreement, Sertoli will exclusively license to Pheromone all patents, and patent applications for the therapeutic use of Sertoli cell technology. In exchange, Pheromone will issue to Sertoli 6,527,500 common shares upon completion of the first project financing of not less than $1 million and nine months after closing pay Sertoli a licensing fee of $1,142,312 in cash or shares.

To fund the first stage of the project, Pheromone anticipates an initial financing of $2 million through a non- brokered private placement of units at $0.40 for one common share and one half warrant exercisable at $0.60 for two years. A finders fee of 7% will be paid and Pheromone will reserve the right to force the exercise of the warrants if the stock trades at a 10 day moving average above $1.00 per share.

About Sertoli

Sertoli Technologies Inc. is a cellular therapy company with platform technology for creating a local immunoprivileged site enabling the therapeutic transplantation of cells and cell-based gene therapy. Sertoli has a comprehensive patent portfolio covering the application of Sertoli cells. Patent applications are filed worldwide in all major markets, including the United States, Europe and Japan. Six U.S. patents have issued containing broad claims that protect the use and application of the Company's technology. The Company is aggressive in the filing of additional patents covering additional therapeutic uses of Sertoli cells and factors derived from Sertoli cells.

Additional Information on Sertoli is available on its website at www.sertoli.com.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

ON BEHALF OF THE BOARD "Dev Randhawa" Dev Randhawa, President

For further information contact: TEL: (250) 868-8177 Mr. Phil Morehouse FAX: (250) 868-8493 Pheromone Sciences Corp.

TEL: (519) 639-7867 Mr. Justin Leushner FAX: (519) 858-5142 Sertonex Inc.

TEL: (520) 748-4458 Ms. Jan McCoy Hutchinson FAX: (520) 748-0025 Sertoli Technologies Inc.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 20, 2006 20 March, 2006

Pheromone Issues Stock Options


Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to announce that it has granted to certain directors, officers and employees of the Company incentive stock options to purchase up to a total of 2,800,000 common shares at a price of $0.40 per share in accordance with the policies of the TSX Venture Exchange.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, President

For further information contact:

TEL: (250) 868-8177 FAX: (250) 868-8493

Mr. Phil Morehouse Pheromone Sciences Corp.